share_log

Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benzinga ·  Dec 4, 2023 09:57

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment